市場調查報告書
商品編碼
1451731
2024-2032年按世代類型、抗癲癇藥物類型、配銷通路和地區分類的癲癇藥物市場Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2024-2032 |
2023年全球癲癇藥物市場規模達23億美元。展望未來, IMARC Group預計到2032年市場規模將達到44億美元,2024-2032年複合年成長率(CAGR)為7.16%。癲癇盛行率的上升、老年人腦癌發生率的增加以及廣泛的研發(R&D)活動是推動市場發展的一些關鍵因素。
癲癇藥物是指用於治療癲癇的藥物,癲癇是一種中樞神經系統 (CNS) 疾病,會導致不可預見的、無端的、反覆發作的癲癇發作。癲癇會影響各種精神和身體功能,導致突然的行為改變、感覺、意識喪失和嚴重的情緒困擾。其藥物包括第一代、第二代和第三代抗癲癇藥物(AED),例如口服、靜脈注射(IV)和肌肉注射途徑給藥的片劑、膠囊、液體和糖漿。癲癇藥物廣泛用於治療各種癲癇發作,包括局部性癲癇發作、難治性癲癇發作、混合性癲癇發作、強直陣攣性癲癇發作和急性反覆癲癇發作。癲癇藥物是安全的,具有更好的耐受性,可以預防危及生命的不良反應,並最大限度地減少對認知功能的負面影響。
目前,由於神經系統疾病、產傷、感染、藥物濫用和道路傷害發病率的增加,癲癇盛行率不斷上升,這是推動市場成長的主要因素之一。癲癇藥物廣泛用於消除癲癇發作、減少癲癇發作頻率、避免長期治療的不良影響,從而幫助患者恢復正常的心理和職業活動,維持正常的生活方式。除此之外,容易罹患嚴重疾病(例如可能導致癲癇發作的腦癌)的老年人口數量不斷增加,也是另一個主要的生長誘導因素。此外,廣泛的研究和開發(R&D)活動旨在開發新的和先進的藥物,這些藥物價格實惠,可提高耐受性和療效,同時減少副作用,目前正在對市場成長產生積極影響。除此之外,最近開發的緩釋(ER)藥物配方允許更長的給藥間隔,同時最大限度地減少血清藥物水平的波動,從而與立即釋放(IR)藥物相比提高療效和依從性,正在促進市場發展生長。此外,政府實施各種措施來教育大眾了解這種疾病、促進研究並透過加速提供更好的治療方案來提供積極支持,正在推動市場成長。其他因素,包括新藥批准的增加、醫療基礎設施的快速改善、公眾對神經系統疾病可用治療方法的認知不斷提高,以及與癲癇相關的恥辱感的減少,預計將推動市場成長。
The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.
Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.
At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.
Generation Type Insights
First Generation Drugs
Phenytoin
Carbamazepine
Oxcarbazepine
Valproate
Ethosuximide
Primidone
Phenobarbital
Second Generation Drugs
Levetiracetam
Lamotrigine
Topiramate
Pregabalin
Rufinamide
Zonisamide
Third Generation Drugs
Lacosamide
Perampanel
Eslicarbazepine Acetate
Ezogabine/Retigabine
The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.
Anti-Epileptics Drugs Type Insights
Narrow-Spectrum AEDs
Broad-Spectrum AEDs
A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.
Distribution Channel Insights
Hospital Pharmacy
Pharmacy Stores
Others
A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report